Plasma levels of transforming growth factor-β1 in renal transplant recipients receiving different immunosuppressive regimens

Transplantation Proceedings

Volumn 36, Issue 3, 2004, Pages 698-699

  Citterio, F ^a   Pozzetto, U ^a   Romagnoli, J ^a   Tondolo, E ^a   Silvestri, P ^a   Nanni, G ^a   Castagneto, M ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA1;

BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CONFERENCE PAPER; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GRAFT REJECTION; HUMAN; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL;

GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; REFERENCE VALUES; RETROSPECTIVE STUDIES; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 2042476723     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.03.014     Document Type: Conference Paper

References (6)

1. Massague J. The transforming growth factor-beta family. Ann Rev Cell Biol. 6:1990;597
2. Border W.A., Okuda S., Languino L.R., et al. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature. 346:1990;371
3. Yamamoto T., Noble N.A., Miller D.E., et al. Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis. Kidney Int. 45:1994;916
4. Hutchinson I.V. The role of transforming growth factor-beta in transplant rejection. Transplant Proc. 31:1999;9S
5. Shin G.T., Khanna A., Ding R., et al. In vivo expression of transforming growth factor-beta 1 in humans stimulation by cyclosporine. Transplantation. 65:1998;313
6. Cohen H., Neild G.H., Patel R., et al. Evidence for chronic platelet hyperaggregability and in vivo activation in cyclosporin-treated renal allograft recipients. Thromb Res. 49:1998;91